Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyMasatoshi Kudo, Yasuaki Arai, Joong‐Won Park et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 200